跳至主要内容
临床试验/NCT06481696
NCT06481696招募中不适用

Randomized, Placebo-controlled, Double-blind, Single-center Trial to Evaluate the Possible Action of Resveratrol in Improving the Outcomes of Controlled Ovarian Stimulation During the IVF/ICSI Cycles in Couples With Unexplained Infertility

Andros Day Surgery Clinic1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
90
试验地点
1
主要终点
FORT (Follicle Output Rate)

研究概览

简要总结

Based on available evidence and given the potential beneficial effects of resveratrol in folliculogenesis and in oocyte development, the investigators designed a randomized, controlled, double-blind, single-center trial, whose objective will be the comparison of biological and clinical outcomes of resveratrol supplement in women undergoing IVF/ICSI cycles for unexplained infertility.

To the knowledge of the investigators, no study has been published on the potential effect of resveratrol on IVF/ICSI outcomes considering couples with this infertility diagnosis, which may be the natural target of this integrative treatment because the process of folliculogenesis and oocyte maturation cannot be routinely investigated. An alteration of these biological mechanisms could be the unrecognized cause of part of the unexplained infertility and treatment with resveratrol could result in significant clinical improvement for the patients enrolled in the study.

In more details, the main objective of this randomized, placebo-controlled, double-blind, single-center trial will be the evaluation of the possible effect of resveratrol in determining a better follicle development in patients with unexplained infertility undergoing controlled ovarian stimulation (COS) for IVF/ICSI.

Infertile female patients with normal ovarian reserve will be treated according to clinical practice and the difference between expected (through AFC) and retrieved oocytes will be assessed in relation to use of resveratrol.

详细描述

On the basis of the last estimates, the global lifetime prevalence of infertility is 17.5%, which means that approximately one in six people have experienced infertility at some stage in their lives.

Despite an improvement in conventional diagnostic investigations, still today, around 25% of the causes of couple infertility remain unexplained.

In fact, several crucial moments of the human reproductive process cannot be studied and, therefore, specific reproductive alterations remain undiagnosed. Just thinking of the process of ovarian folliculogenesis, oocyte development, embryonic implantation, all ones real "biological mysteries".

Among these different biological aspects, it is known that the oocyte quality is the main predictor of clinical pregnancy after IVF/ICSI. Indeed, oocyte maturation process influences the embryo development and, consequently, the embryo viability. Although the mechanisms that determine a good quality oocyte are not known, nevertheless energy-dependent processes are supposed to play a major role in oocyte development. These processes are mediated by mitochondria, whose concentration in oocytes is the highest among the other cells of human body. The oocyte nuclear and cytoplasmic maturation is strictly connected with the growth of granulosa cells (GCs). These cells surround the oocyte and establish a functional bidirectional cross-talk with the oocyte itself through gap junctions and paracrine factors. During folliculogenesis, GCs increase the consumption of glucose and metabolize glucose into pyruvate which passes to the oocyte. All this determines an increase in the energy supply to the oocyte itself, demonstrated by the increase in ATP production, which allows the latter cell to prepare for fertilization and the first stages of embryonic development which, as known, is totally oocyte dependent .

Resveratrol seems to be able to fit into this area of cellular functioning. It is a natural polyphenol, widespread in foods, plants, drinks and it seems to induce GCs proliferation through an anti-apoptotic effect in a SIRT1-dependent manner. Furthermore, in GCs, resveratrol reduces the oxidative stress, increases the mitochondria biogenesis and the intracellular ATP levels, determining a high energy availability which favours the oocyte growth. Resveratrol seems to reduce in rat granulosa cells the expression of Vascular Endothelial Growth Factor (VEGF), implicated in angiogenesis and vascular permeability, potentially showing a protective effect on the risk of Ovarian Hyperstimulation Syndrome (OHSS), a life-threatening condition associated with ovarian stimulation, whose VEGF is the main mediator.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female age 18-40 years
  • Female BMI 18-30 kg/m2
  • normal menstrual cycles (26-35 days)
  • duration of infertility at least 18 months
  • normal semen parameters as established by WHO laboratory manual for the examination and processing of human semen Sixth edition
  • normal US evaluation of male genital anatomy
  • normal FSH, LH, Prolactin, Total Testosterone, Estradiol in male partner
  • bilateral tubal patency established by 3-D HyFoSy or HSG
  • normal uterine cavity evaluated by 3-D HyFoSy or HSG or hysteroscopy
  • absence of antibodies Anti-Chlamyidia Trachomatis IgG/IgM
  • failed intrauterine inseminations or couple's decision to refuse intrauterine inseminations

排除标准

  • ≥15 cigarettes per day at least in one of the partners
  • irregular menstrual cycles
  • poor ovarian response (on the basis of the "Bologna" Criteria)
  • inaccessible ovaries
  • severe endometriosis (stage III-IV of the ASRM revised classification)
  • significant systemic diseases
  • heterologous fertilization
  • previous pelvic surgery
  • presence of ovarian cysts
  • polycystic ovary syndrome
  • use of hormonal contraception in the previous 3 months
  • use of gonadotrophins in the previous 3 months
  • III stage varicocele

研究组 & 干预措施

Resveratrol group

Active Comparator

Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Resveratrol-based multivitamin supplement (Dietary Supplement)

Resveratrol group

Active Comparator

Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: IVF/ICSI (Procedure)

Resveratrol group

Active Comparator

Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Follitropin Alfa (Drug)

Resveratrol group

Active Comparator

Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Ganirelix Acetate 0.5 MG/ML [Fyremadel] (Drug)

Resveratrol group

Active Comparator

Treatment with resveratrol, folic acid and vitamins B6, B12, D. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously (Drug)

Placebo group

Active Comparator

Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Folic acid (Dietary Supplement)

Placebo group

Active Comparator

Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: IVF/ICSI (Procedure)

Placebo group

Active Comparator

Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Follitropin Alfa (Drug)

Placebo group

Active Comparator

Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: Ganirelix Acetate 0.5 MG/ML [Fyremadel] (Drug)

Placebo group

Active Comparator

Treatment with folic acid only. The duration of treatment will be at least 65 days before the starting of stimulation (from the stage of pre-antral follicles) and until the day of oocyte pick up.

干预措施: hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously (Drug)

结局指标

主要结局

FORT (Follicle Output Rate)

时间窗: The assessment will be performed at the end of stimulation (11°-15° day of a menstrual cycle of 28 days)

It is defined as the ratio of pre-ovulatory follicle (≥ 16 mm in diameter) count (PFC) on the day of induction of oocyte maturation and the antral follicle count at baseline, multiplied by 100 (higher values indicate a better outcome).

FOI (Follicle to Oocyte Index)

时间窗: The assessment will be performed at the end of oocyte pick up (2 hours after the oocyte pick up)

It is defined by the ratio between the total number of oocytes collected at oocyte pick up and the number of antral follicles at baseline, multiplied by 100. FOI ≤ 50% is considered low (range 0-100%).

The number of mature oocytes

时间窗: The assessment will be performed after the oocyte pick up (2 hours after the oocyte pick up)

The number of oocytes which have completed the metaphase-II division

OSI (Ovarian Sensitivity Index)

时间窗: The assessment will be performed at the end of oocyte pick up (2 hours after the oocyte pick up)

It is defined by the ratio between the number of retrieved oocytes and total dose of gonadotropins administered, multiplied by 1000.

次要结局

  • Fertilization rate(The assessment will be carried out the day after the insemination (one day after the oocyte pick up).)
  • Cumulative Clinical Pregnancy Rate(The assessment will be carried out at 7th week of amenorrhea.)

研究者

发起方
Andros Day Surgery Clinic
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验